# Johnson & Johnson Stock Surges Following Stellar Q4 Results and Analyst Upgrades | Investment Analysis

Discover why Johnson & Johnson (JNJ) shares are gaining momentum as we analyze the stock's recent 1.5% climb to $227.70. This episode unpacks JNJ's impressive Q4 performance that exceeded Wall Street expectations, with quarterly revenue reaching $24.6 billion and EPS of $2.46. Learn about the company's ambitious FY2026 guidance projecting $100-101 billion in sales—surpassing consensus estimates by over $1.5 billion.

We examine the wave of analyst upgrades, including Morgan Stanley's notable shift from Equalweight to Overweight with a $262 price target suggesting nearly 17% upside potential. Find out why 14 of 26 analysts now rate JNJ as a "buy" despite the CEO's recent $22.1 million stock sale.

With strong institutional backing, solid fundamentals, and increasing analyst confidence, we evaluate whether Johnson & Johnson's current trajectory makes it a worthwhile addition to your investment portfolio. Don't miss our comprehensive analysis of this healthcare giant's market position and future prospects.

#JohnsonAndJohnson #StockAnalysis #InvestmentOpportunities #HealthcareStocks #WallStreetUpgrades #StockMarketAnalysis #FinancialResults

For more http://www.quietplease.ai

Stock up on these deals
https://amzn.to/3QFpYIX

This content was created in partnership and with the help of Artificial Intelligence AI